JP5675771B2 - 精神神経疾患の治療をモニタリングするためのバイオマーカー - Google Patents
精神神経疾患の治療をモニタリングするためのバイオマーカー Download PDFInfo
- Publication number
- JP5675771B2 JP5675771B2 JP2012503731A JP2012503731A JP5675771B2 JP 5675771 B2 JP5675771 B2 JP 5675771B2 JP 2012503731 A JP2012503731 A JP 2012503731A JP 2012503731 A JP2012503731 A JP 2012503731A JP 5675771 B2 JP5675771 B2 JP 5675771B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- score
- markers
- diagnostic
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims description 91
- 239000000090 biomarker Substances 0.000 title description 131
- 238000012544 monitoring process Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims description 104
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 102
- 238000011491 transcranial magnetic stimulation Methods 0.000 claims description 69
- 201000010099 disease Diseases 0.000 claims description 57
- 239000012472 biological sample Substances 0.000 claims description 54
- 208000035475 disorder Diseases 0.000 claims description 45
- 230000004044 response Effects 0.000 claims description 28
- 230000002503 metabolic effect Effects 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 19
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 16
- 230000004054 inflammatory process Effects 0.000 claims description 16
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 9
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 8
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 8
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 102000003946 Prolactin Human genes 0.000 claims description 4
- 108010057464 Prolactin Proteins 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 229940097325 prolactin Drugs 0.000 claims description 4
- 102000007156 Resistin Human genes 0.000 claims description 3
- 108010047909 Resistin Proteins 0.000 claims description 3
- 230000004797 therapeutic response Effects 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 32
- 230000003285 pharmacodynamic effect Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 16
- 239000012491 analyte Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 10
- 238000013456 study Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000011269 treatment regimen Methods 0.000 description 8
- 208000020401 Depressive disease Diseases 0.000 description 7
- 239000000935 antidepressant agent Substances 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 7
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 238000004590 computer program Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000003900 neurotrophic factor Substances 0.000 description 7
- 210000002442 prefrontal cortex Anatomy 0.000 description 7
- 238000009225 cognitive behavioral therapy Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000000508 neurotrophic effect Effects 0.000 description 6
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229940054157 lexapro Drugs 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000007620 mathematical function Methods 0.000 description 4
- 238000010320 meditation therapy Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 238000001050 pharmacotherapy Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000013548 repetitive transcranial magnetic stimulation Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000002635 electroconvulsive therapy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 108091061482 Glial cell line-derived neurotrophic factor family Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- -1 serum amyloid P Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Primary Health Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16566209P | 2009-04-01 | 2009-04-01 | |
| US61/165,662 | 2009-04-01 | ||
| PCT/US2010/029720 WO2010115061A2 (en) | 2009-04-01 | 2010-04-01 | Biomarkers for monitoring treatment of neuropsychiatric diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522995A JP2012522995A (ja) | 2012-09-27 |
| JP2012522995A5 JP2012522995A5 (cg-RX-API-DMAC10.html) | 2013-05-16 |
| JP5675771B2 true JP5675771B2 (ja) | 2015-02-25 |
Family
ID=42828950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503731A Expired - Fee Related JP5675771B2 (ja) | 2009-04-01 | 2010-04-01 | 精神神経疾患の治療をモニタリングするためのバイオマーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100280760A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2414824B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5675771B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN102483398A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2757518A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010115061A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158374B1 (en) | 2006-09-05 | 2012-04-17 | Ridge Diagnostics, Inc. | Quantitative diagnostic methods using multiple parameters |
| JP5540000B2 (ja) * | 2008-10-15 | 2014-07-02 | リッジ ダイアグノスティックス，インコーポレイテッド | うつ病性障害のヒトバイオマーカーハイパーマッピング |
| WO2010059709A2 (en) * | 2008-11-18 | 2010-05-27 | Ridge Diagnostics, Inc. | Metabolic syndrome and hpa axis biomarkers for major depressive disorder |
| US20120178118A1 (en) * | 2010-12-06 | 2012-07-12 | Bo Pi | Biomarkers for monitoring treatment of neuropsychiatric diseases |
| CA2757659A1 (en) * | 2009-04-06 | 2010-10-14 | Ridge Diagnostics, Inc. | Biomarkers for monitoring treatment of neuropsychiatric diseases |
| WO2011094308A2 (en) * | 2010-01-26 | 2011-08-04 | Ridge Diagnostics, Inc. | Multiple biomarker panels to stratify disease severity and monitor treatment of depression |
| AU2012329088A1 (en) * | 2011-10-24 | 2014-05-29 | President And Fellows Of Harvard College | Enhancing diagnosis of disorder through artificial intelligence and mobile health technologies without compromising accuracy |
| ES3067417T3 (en) | 2015-08-11 | 2026-05-21 | Cognoa Inc | Apparatus to determine developmental progress with artificial intelligence and user input |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| CN109715194B (zh) | 2016-08-03 | 2024-06-11 | 南佛罗里达大学 | 用于治疗神经障碍的颤蛋白组合物 |
| CN118609834A (zh) | 2016-11-14 | 2024-09-06 | 科格诺亚公司 | 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置 |
| JP7324709B2 (ja) | 2017-02-09 | 2023-08-10 | コグノア，インク． | デジタル個別化医療のためのプラットフォームとシステム |
| CN109568795B (zh) * | 2018-11-23 | 2023-01-24 | 中国医学科学院生物医学工程研究所 | 基于脑电溯源和线性相关的脑深部磁刺激靶点定位方法 |
| CN113873935B (zh) | 2019-03-22 | 2024-11-22 | 科格诺亚公司 | 个性化数字化治疗方法和装置 |
| KR102365373B1 (ko) * | 2019-07-19 | 2022-02-21 | 연세대학교 산학협력단 | 재활 운동에 대한 치료 반응 예측 방법 및 키트 |
| WO2021046412A1 (en) | 2019-09-06 | 2021-03-11 | Cognoa, Inc. | Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments |
| KR20220167321A (ko) * | 2020-07-02 | 2022-12-20 | 페어 테라퓨틱스 (유에스), 인코포레이티드 | 디지털 치료 위약 및 샴을 생성 및 관리하기 위한 시스템, 방법 및 디바이스 |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
| US20260188467A1 (en) * | 2024-12-27 | 2026-07-02 | Center for Social Dynamics, LLC | Parallel Processing Systems and Methods For Real-Time Multimodal Behavioral Classification Using Neural Networks With Dynamic Content Adaptation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123938A1 (en) * | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| WO2002057790A2 (en) | 2001-01-19 | 2002-07-25 | Mindsense Biosystems Ltd. | Methods and compositions for diagnosing and treating a subject having depression |
| US20040152107A1 (en) * | 2002-09-18 | 2004-08-05 | C. Anthony Altar | Gene signature of electroshock therapy and methods of use |
| US7490085B2 (en) * | 2002-12-18 | 2009-02-10 | Ge Medical Systems Global Technology Company, Llc | Computer-assisted data processing system and method incorporating automated learning |
| US7706871B2 (en) * | 2003-05-06 | 2010-04-27 | Nellcor Puritan Bennett Llc | System and method of prediction of response to neurological treatment using the electroencephalogram |
| US7418290B2 (en) * | 2003-05-06 | 2008-08-26 | Aspect Medical Systems, Inc. | System and method of assessment of the efficacy of treatment of neurological disorders using the electroencephalogram |
| US20050084880A1 (en) * | 2003-07-11 | 2005-04-21 | Ronald Duman | Systems and methods for diagnosing & treating psychological and behavioral conditions |
| JP2005312435A (ja) | 2004-03-29 | 2005-11-10 | Kazuhito Rokutan | うつ病の評価方法 |
| KR20050115436A (ko) | 2004-06-02 | 2005-12-07 | 김은아 | 우울증 치료에 사용되는 '반복적 경두개 자기장 법'에 의하여 발현이 변화되는 흰쥐 뇌의 해마 유전자군. |
| JP2007024822A (ja) * | 2005-07-21 | 2007-02-01 | Aska Pharmaceutical Co Ltd | 男性の更年期又はうつ病の鑑別方法 |
| JP2009516156A (ja) * | 2005-10-18 | 2009-04-16 | ケンブリッジ エンタープライズ リミティッド | 精神病性障害を診断及びモニタリングする方法及びバイオマーカー |
| US8673650B2 (en) | 2005-12-09 | 2014-03-18 | Ridge Diagnostics, Inc. | Optical molecular detection |
| HRP20140673T1 (hr) * | 2006-02-17 | 2014-10-10 | Atsuo Sekiyama | Indikator biološkog materijala i postupak mjerenja biološkog materijala |
| US20080015465A1 (en) * | 2006-06-15 | 2008-01-17 | Scuderi Gaetano J | Methods for diagnosing and treating pain in the spinal cord |
| US7651836B2 (en) * | 2006-08-04 | 2010-01-26 | Hospital Santiago Apóstol | Methods for diagnosis and prognostic of psychiatric diseases |
| US8158374B1 (en) * | 2006-09-05 | 2012-04-17 | Ridge Diagnostics, Inc. | Quantitative diagnostic methods using multiple parameters |
| US20080199866A1 (en) * | 2006-10-10 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Snp detection and other methods for characterizing and treating bipolar disorder and other ailments |
| US20080281531A1 (en) | 2007-03-15 | 2008-11-13 | Kazuhito Rokutan | Method for Diagnosing Depression |
| CN102037355A (zh) * | 2008-03-04 | 2011-04-27 | 里奇诊断学股份有限公司 | 基于多重生物标记物板块诊断和监测抑郁症 |
| EP2272044A4 (en) * | 2008-03-12 | 2011-07-06 | Ridge Diagnostics Inc | INFLAMMATORY BIOMARKING FOR MONITORING DEPRESSION DISEASES |
| US20120178118A1 (en) * | 2010-12-06 | 2012-07-12 | Bo Pi | Biomarkers for monitoring treatment of neuropsychiatric diseases |
| CA2757659A1 (en) * | 2009-04-06 | 2010-10-14 | Ridge Diagnostics, Inc. | Biomarkers for monitoring treatment of neuropsychiatric diseases |
| WO2011094308A2 (en) * | 2010-01-26 | 2011-08-04 | Ridge Diagnostics, Inc. | Multiple biomarker panels to stratify disease severity and monitor treatment of depression |
-
2010
- 2010-04-01 JP JP2012503731A patent/JP5675771B2/ja not_active Expired - Fee Related
- 2010-04-01 CA CA2757518A patent/CA2757518A1/en not_active Abandoned
- 2010-04-01 CN CN2010800223067A patent/CN102483398A/zh active Pending
- 2010-04-01 US US12/753,022 patent/US20100280760A1/en not_active Abandoned
- 2010-04-01 WO PCT/US2010/029720 patent/WO2010115061A2/en not_active Ceased
- 2010-04-01 EP EP10759446.7A patent/EP2414824B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| CN102483398A (zh) | 2012-05-30 |
| US20100280760A1 (en) | 2010-11-04 |
| JP2012522995A (ja) | 2012-09-27 |
| WO2010115061A9 (en) | 2011-01-20 |
| WO2010115061A2 (en) | 2010-10-07 |
| EP2414824A4 (en) | 2012-09-05 |
| EP2414824A2 (en) | 2012-02-08 |
| CA2757518A1 (en) | 2010-10-07 |
| EP2414824B1 (en) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2414824B1 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| JP2012523009A (ja) | 精神神経疾患の治療をモニタリングするためのバイオマーカー | |
| JP5663314B2 (ja) | 多数のバイオマーカーパネルに基づくうつ障害の診断およびモニタリング | |
| JP5658571B2 (ja) | うつ障害をモニタリングするための炎症バイオマーカー | |
| JP5744063B2 (ja) | うつ病の疾患重症度を層別化するためおよび処置をモニタリングするための複数のバイオマーカーパネル | |
| US20170131295A1 (en) | Multiple biomarker panels to stratify disease severity and monitor treatment of depression | |
| JP5540000B2 (ja) | うつ病性障害のヒトバイオマーカーハイパーマッピング | |
| JP2014500503A (ja) | 精神神経疾患の処置をモニタリングするためのバイオマーカー | |
| JP5767973B2 (ja) | 大うつ病性障害のためのメタボリック症候群バイオマーカーおよびｈｐａ軸バイオマーカー | |
| US20160342757A1 (en) | Diagnosing and monitoring depression disorders | |
| US20170161441A1 (en) | Methods and materials for treating pain and depression | |
| HK1171807A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1171081A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1190789A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1164379A (en) | Human biomarker hypermapping for depressive disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130329 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131225 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131226 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140320 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140328 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140605 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141126 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141224 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5675771 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |